Since the introduction of disulfiram in 1951 (the first ever Food and Drug Administration (FDA)-approved medication for substance use disorders (SUDs)) (1), only seven other individual medications have been approved for the treatment of SUDs. While the repurpose of medications and different formulations increase the total number of FDA-approved medicines (Table 1 and(2)), the arsenal of...
Abstract Background Cannabis use is a well-established environmental risk factor for psychosis and auditory hallucinations, yet the neurobiological mechanisms underlying this association remain incompletely understood. Neuroimaging studies of psychotic disorders have consistently implicated structural abnormalities within auditory and temporoparietal cortical networks involved in speech...